Constellation Pharmaceuticals, Inc. (CNST) financial statements (2022 and earlier)

Company profile

Business Address 215 FIRST STREET
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

Current Assets
Cash, cash equivalents, and short-term investments421,448383,934114,592
Cash and cash equivalents163,693334,332114,592
Short-term investments257,75549,602 
Other undisclosed current assets7,1613,0552,711
Total current assets:428,609386,989117,303
Noncurrent Assets
Operating lease, right-of-use asset3,54110,745
Property, plant and equipment1,4979711,210
Restricted cash and investments3,233425425
Other undisclosed noncurrent assets4,974  
Total noncurrent assets:13,24512,1411,635
TOTAL ASSETS:441,854399,130118,938
Current Liabilities
Accounts payable and accrued liabilities15,86511,9898,704
Accounts payable9,8537,2785,723
Accrued liabilities467184255
Employee-related liabilities5,5454,5272,726
Debt 2,562 
Other liabilities341497346
Other undisclosed current liabilities14,3427,7075,610
Total current liabilities:30,54822,75514,660
Noncurrent Liabilities
Long-term debt and lease obligation58238,401 
Long-term debt, excluding current maturities 29,642 
Operating lease, liability5828,759
Liabilities, other than long-term debt 390120
Deferred rent credit  118
Other liabilities 3902
Other undisclosed noncurrent liabilities(582)  
Total noncurrent liabilities:58238,791120
Total liabilities:31,13061,54614,780
Stockholders' equity
Stockholders' equity attributable to parent410,724337,584104,158
Common stock543
Additional paid in capital856,460656,973337,992
Accumulated other comprehensive income (loss)3(6) 
Accumulated deficit(445,744)(319,387)(233,837)
Total stockholders' equity:410,724337,584104,158
TOTAL LIABILITIES AND EQUITY:441,854399,130118,938

Income statement (P&L) ($ in thousands)

(Sublease Income)
Gross profit:220199 
Operating expenses(124,847)(86,055)(61,244)
Other undisclosed operating loss(220)(199) 
Operating loss:(124,847)(86,055)(61,244)
Nonoperating income (expense)(1,471)5291,319
Investment income, nonoperating2,8512,6441,547
Interest and debt expense(1,501)(2,115)(228)
Loss from continuing operations before equity method investments, income taxes:(127,819)(87,641)(60,153)
Other undisclosed income from continuing operations before income taxes1,5012,115 
Loss from continuing operations before income taxes:(126,318)(85,526)(60,153)
Income tax expense(39)(24) 
Loss before gain (loss) on sale of properties:(126,357)(85,550)(60,153)
Other undisclosed net income  228
Net loss attributable to parent:(126,357)(85,550)(59,925)
Other undisclosed net loss available to common stockholders, basic (6) 
Net loss available to common stockholders, diluted:(126,357)(85,556)(59,925)

Comprehensive Income ($ in thousands)

Net loss:(126,357)(85,550)(59,925)
Comprehensive loss:(126,357)(85,550)(59,925)
Other undisclosed comprehensive income, net of tax, attributable to parent9  
Comprehensive loss, net of tax, attributable to parent:(126,348)(85,550)(59,925)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: